[The role of genetic polymorphisms of cytochrome P450 in drug metabolism used in the treatment of cardiovascular diseases].
Wojtczak
Anna
A
Zakład Farmakogenetyki, Uniwersytet Medyczny, Łódź. awojt@mp.pl
Skretkowicz
Jadwiga
J
D000284:Administration, Oral; D000319:Adrenergic beta-Antagonists / Q000378:metabolism; D047228:Angiotensin II Type 1 Receptor Blockers / Q000378:metabolism; D000889:Anti-Arrhythmia Agents / Q000378:metabolism; D000925:Anticoagulants / Q000008:administration & dosage / Q000378:metabolism; D002121:Calcium Channel Blockers / Q000378:metabolism; D002317:Cardiovascular Agents / Q000378:metabolism*; D002318:Cardiovascular Diseases / Q000188:drug therapy*; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000378:metabolism; D010975:Platelet Aggregation Inhibitors / Q000378:metabolism; D011110:Polymorphism, Genetic
D000319:Adrenergic beta-Antagonists; D047228:Angiotensin II Type 1 Receptor Blockers; D000889:Anti-Arrhythmia Agents; D000925:Anticoagulants; D002121:Calcium Channel Blockers; D002317:Cardiovascular Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D010975:Platelet Aggregation Inhibitors; D003577:Cytochrome P-450 Enzyme System